Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors.

Merlino G, Fiascarelli A, Bigioni M, Bressan A, Carrisi C, Bellarosa D, Salerno M, Bugianesi R, Manno R, Bernadó Morales C, Arribas J, Dusek RL, Ackroyd JE, Pham PH, Awdew R, Aud D, Trang M, Lynch CM, Terrett J, Wilson KE, Rohlff C, Manzini S, Pellacani A, Binaschi M.

Mol Cancer Ther. 2019 Sep;18(9):1533-1543. doi: 10.1158/1535-7163.MCT-18-0624. Epub 2019 Jun 21.

PMID:
31227646
2.

Proteomic screening identifies calreticulin as a miR-27a direct target repressing MHC class I cell surface exposure in colorectal cancer.

Colangelo T, Polcaro G, Ziccardi P, Pucci B, Muccillo L, Galgani M, Fucci A, Milone MR, Budillon A, Santopaolo M, Votino C, Pancione M, Piepoli A, Mazzoccoli G, Binaschi M, Bigioni M, Maggi CA, Fassan M, Laudanna C, Matarese G, Sabatino L, Colantuoni V.

Cell Death Dis. 2016 Feb 25;7:e2120. doi: 10.1038/cddis.2016.28.

3.

Benzofused hydroxamic acids: useful fragments for the preparation of histone deacetylase inhibitors. Part 2: 7-fluorobenzothiophenes and benzofurans.

Marastoni E, Bartoli S, Berettoni M, Cipollone A, Ettorre A, Fincham CI, Mauro S, Paris M, Porcelloni M, Bigioni M, Binaschi M, Nardelli F, Parlani M, Maggi CA, Paoli P, Rossi P, Fattori D.

Bioorg Med Chem Lett. 2015 Apr 1;25(7):1603-6. doi: 10.1016/j.bmcl.2015.02.007. Epub 2015 Feb 24.

PMID:
25746815
4.

MicroRNA-130b promotes tumor development and is associated with poor prognosis in colorectal cancer.

Colangelo T, Fucci A, Votino C, Sabatino L, Pancione M, Laudanna C, Binaschi M, Bigioni M, Maggi CA, Parente D, Forte N, Colantuoni V.

Neoplasia. 2013 Sep;15(9):1086-99.

5.

Benzofused hydroxamic acids: useful fragments for the preparation of histone deacetylase inhibitors. Part 1: hit identification.

Marastoni E, Bartoli S, Berettoni M, Cipollone A, Ettorre A, Fincham CI, Mauro S, Paris M, Porcelloni M, Bigioni M, Binaschi M, Nardelli F, Parlani M, Maggi CA, Fattori D.

Bioorg Med Chem Lett. 2013 Jul 15;23(14):4091-5. doi: 10.1016/j.bmcl.2013.05.053. Epub 2013 May 25.

PMID:
23768910
6.

OC125, M11 and OV197 epitopes are not uniformly distributed in the tandem-repeat region of CA125 and require the entire SEA domain.

Bressan A, Bozzo F, Maggi CA, Binaschi M.

Dis Markers. 2013;34(4):257-67. doi: 10.3233/DMA-130968.

7.

Set-up of a new series of HDAC inhibitors: the 5,11-dihydrodibenzo[b,e]azepin-6-ones as privileged structures.

Bigioni M, Ettorre A, Felicetti P, Mauro S, Rossi C, Maggi CA, Marastoni E, Binaschi M, Parlani M, Fattori D.

Bioorg Med Chem Lett. 2012 Sep 1;22(17):5360-2. doi: 10.1016/j.bmcl.2012.07.067. Epub 2012 Jul 26.

PMID:
22877635
8.

SAHA/Vorinostat induces the expression of the CD137 receptor/ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line.

Bellarosa D, Bressan A, Bigioni M, Parlani M, Maggi CA, Binaschi M.

Int J Oncol. 2012 Oct;41(4):1486-94. doi: 10.3892/ijo.2012.1551. Epub 2012 Jul 13.

PMID:
22797667
9.

Synthesis and biological evaluation of rebeccamycin analogues modified at the imide moiety.

Animati F, Berettoni M, Bigioni M, Binaschi M, Cipollone A, Irrissuto C, Nardelli F, Olivieri L.

Bioorg Med Chem Lett. 2012 Aug 1;22(15):5013-7. doi: 10.1016/j.bmcl.2012.06.016. Epub 2012 Jun 15.

PMID:
22749423
10.

4-N-Hydroxy-4-[1-(sulfonyl)piperidin-4-yl]-butyramides as HDAC inhibitors.

Rossi C, Fincham CI, D'Andrea P, Porcelloni M, Ettorre A, Mauro S, Bigioni M, Binaschi M, Maggi CA, Nardelli F, Parlani M, Fattori D.

Bioorg Med Chem Lett. 2011 Nov 15;21(22):6767-9. doi: 10.1016/j.bmcl.2011.09.042. Epub 2011 Sep 18.

PMID:
21978679
11.

Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors.

Rossi C, Porcelloni M, D'Andrea P, Fincham CI, Ettorre A, Mauro S, Squarcia A, Bigioni M, Parlani M, Nardelli F, Binaschi M, Maggi CA, Fattori D.

Bioorg Med Chem Lett. 2011 Apr 15;21(8):2305-8. doi: 10.1016/j.bmcl.2011.02.085. Epub 2011 Feb 26.

PMID:
21420859
12.

Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach.

Binaschi M, Simonelli C, Goso C, Bigioni M, Maggi CA.

Exp Ther Med. 2011 Mar;2(2):173-180. Epub 2011 Jan 14.

13.

Antiproliferative and differentiating activities of a novel series of histone deacetylase inhibitors.

Binaschi M, Boldetti A, Gianni M, Maggi CA, Gensini M, Bigioni M, Parlani M, Giolitti A, Fratelli M, Valli C, Terao M, Garattini E.

ACS Med Chem Lett. 2010 Jul 20;1(8):411-5. doi: 10.1021/ml1001163. eCollection 2010 Nov 11.

14.

Induction of a less aggressive phenotype in human colon carcinoma HCT116 cells by chronic exposure to HDAC inhibitor SAHA.

Bressan A, Bigioni M, Bellarosa D, Nardelli F, Irrissuto C, Maggi CA, Binaschi M.

Oncol Rep. 2010 Nov;24(5):1249-55.

PMID:
20878117
15.

Antitumor activity of delimotecan against human metastatic melanoma: pharmacokinetics and molecular determinants.

Bigioni M, Parlani M, Bressan A, Bellarosa D, Rivoltini L, Animati F, Crea A, Bugianesi R, Maggi CA, Manzini S, Binaschi M.

Int J Cancer. 2009 Nov 15;125(10):2456-64. doi: 10.1002/ijc.24661.

16.

Histone deacetylase inhibitors: from bench to clinic.

Paris M, Porcelloni M, Binaschi M, Fattori D.

J Med Chem. 2008 Mar 27;51(6):1505-29. doi: 10.1021/jm7011408. Epub 2008 Feb 5. Review. No abstract available. Erratum in: J Med Chem. 2008 Jun 12;51(11):3330.

PMID:
18247554
17.

Sabarubicin (MEN10755)-induced apoptosis is independent from mtDNA in A2780 human ovarian tumor cells.

Bressan A, Nardelli F, Bellarosa D, Bigioni M, Curcurù G, Curatella B, Crea A, Maggi CA, Manzini S, Binaschi M.

Anticancer Res. 2007 Nov-Dec;27(6B):4039-46.

18.

Synthesis, biological evaluation, and molecular modeling studies of rebeccamycin analogues modified in the carbohydrate moiety.

Animati F, Berettoni M, Bigioni M, Binaschi M, Felicetti P, Gontrani L, Incani O, Madami A, Monteagudo E, Olivieri L, Resta S, Rossi C, Cipollone A.

ChemMedChem. 2008 Feb;3(2):266-79.

PMID:
18157856
19.

Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.

Bigioni M, Benzo A, Irrissuto C, Lopez G, Curatella B, Maggi CA, Manzini S, Crea A, Caroli S, Cubadda F, Binaschi M.

Cancer Chemother Pharmacol. 2008 Sep;62(4):621-9. Epub 2007 Nov 24.

PMID:
18038274
20.

Human and murine macrophages mediate activation of MEN 4901/T-0128: a new promising camptothecin analogue-polysaccharide conjugate.

Binaschi M, Parlani M, Bellarosa D, Bigioni M, Salvatore C, Palma C, Crea A, Maggi CA, Manzini S, Goso C.

Anticancer Drugs. 2006 Nov;17(10):1119-26.

PMID:
17075311
21.
22.

NF-kappaB activation contributes to anthracycline resistance pathway in human ovarian carcinoma cell line A2780.

Salvatore C, Camarda G, Maggi CA, Goso C, Manzini S, Binaschi M.

Int J Oncol. 2005 Sep;27(3):799-806.

PMID:
16077931
23.

Involvement of nitric oxide in both central and peripheral haemodynamic effect of D/L-nebivolol and its enantiomers in rats.

Sacco G, Evangelista S, Criscuoli M, Goso C, Bigioni M, Binaschi M, Manzini S, Maggi CA.

Eur J Pharmacol. 2005 Mar 28;511(2-3):167-74.

PMID:
15792785
24.

Effects of common buffer systems on drug activity: the case of clerocidin.

Richter S, Fabris D, Binaschi M, Gatto B, Capranico G, Palumbo M.

Chem Res Toxicol. 2004 Apr;17(4):492-501.

PMID:
15089091
25.

MEN15658: a new promising anti-tumoral drug active on resistant tumor cells.

Salvatore C, Binaschi M, Bigioni M, Camarda G, Maggi CA, Goso C.

Anticancer Drugs. 2004 Feb;15(2):151-6.

PMID:
15075671
26.

CD137 and CD137 ligand constitutively coexpressed on human T and B leukemia cells signal proliferation and survival.

Palma C, Binaschi M, Bigioni M, Maggi CA, Goso C.

Int J Cancer. 2004 Jan 20;108(3):390-8.

27.

Anthracyclines: selected new developments.

Binaschi M, Bigioni M, Cipollone A, Rossi C, Goso C, Maggi CA, Capranico G, Animati F.

Curr Med Chem Anticancer Agents. 2001 Aug;1(2):113-30. Review.

PMID:
12678762
28.
29.

Novel anthracycline oligosaccharides: influence of chemical modifications of the carbohydrate moiety on biological activity.

Cipollone A, Berettoni M, Bigioni M, Binaschi M, Cermele C, Monteagudo E, Olivieri L, Palomba D, Animati F, Goso C, Maggi CA.

Bioorg Med Chem. 2002 May;10(5):1459-70.

PMID:
11886808
30.

Loss of drug-stimulated topoisomerase II DNA breaks in living cells is different at two unrelated loci.

Binaschi M, Borgnetto ME, Capranico G.

Nucleic Acids Res. 2000 Sep 1;28(17):3289-93.

31.

In vivo site specificity and human isoenzyme selectivity of two topoisomerase II-poisoning anthracyclines.

Binaschi M, Farinosi R, Borgnetto ME, Capranico G.

Cancer Res. 2000 Jul 15;60(14):3770-6.

32.

Detection of cellular DNA cleavage using non-proofreading thermostable DNA polymerases.

Binaschi M, Farinosi R, Borgnetto ME, Capranico G.

Biotechniques. 2000 Jun;28(6):1064-6. No abstract available.

33.

Tethering a type IB topoisomerase to a DNA site by enzyme fusion to a heterologous site-selective DNA-binding protein domain.

Beretta GL, Binaschi M, Zagni E, Capuani L, Capranico G.

Cancer Res. 1999 Aug 1;59(15):3689-97.

34.

Topoisomerase poisoning activity of novel disaccharide anthracyclines.

Guano F, Pourquier P, Tinelli S, Binaschi M, Bigioni M, Animati F, Manzini S, Zunino F, Kohlhagen G, Pommier Y, Capranico G.

Mol Pharmacol. 1999 Jul;56(1):77-84.

PMID:
10385686
35.

DNA sequence selectivity of topoisomerases and topoisomerase poisons.

Capranico G, Binaschi M.

Biochim Biophys Acta. 1998 Oct 1;1400(1-3):185-94. Review.

PMID:
9748568
36.

Human DNA topoisomerase IIalpha-dependent DNA cleavage and yeast cell killing by anthracycline analogues.

Binaschi M, Farinosi R, Austin CA, Fisher LM, Zunino F, Capranico G.

Cancer Res. 1998 May 1;58(9):1886-92.

37.

A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons.

Capranico G, Binaschi M, Borgnetto ME, Zunino F, Palumbo M.

Trends Pharmacol Sci. 1997 Sep;18(9):323-9. Review.

PMID:
9345851
38.
39.

Irreversible and reversible topoisomerase II DNA cleavage stimulated by clerocidin: sequence specificity and structural drug determinants.

Binaschi M, Zagotto G, Palumbo M, Zunino F, Farinosi R, Capranico G.

Cancer Res. 1997 May 1;57(9):1710-6.

40.

MRP gene overexpression in a human doxorubicin-resistant SCLC cell line: alterations in cellular pharmacokinetics and in pattern of cross-resistance.

Binaschi M, Supino R, Gambetta RA, Giaccone G, Prosperi E, Capranico G, Cataldo I, Zunino F.

Int J Cancer. 1995 Jul 4;62(1):84-9.

PMID:
7601572
41.

Mechanism of action of DNA topoisomerase inhibitors.

Binaschi M, Zunino F, Capranico G.

Stem Cells. 1995 Jul;13(4):369-79. Review.

PMID:
7549896
42.

Influence of structural modifications at the 3' and 4' positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome multidrug resistance.

Capranico G, Supino R, Binaschi M, Capolongo L, Grandi M, Suarato A, Zunino F.

Mol Pharmacol. 1994 May;45(5):908-15.

PMID:
8190107
43.

A study of cross-resistance pattern and expression of molecular markers of multidrug resistance in a human small-cell lung-cancer cell line selected with doxorubicin.

Supino R, Binaschi M, Capranico G, Gambetta RA, Prosperi E, Sala E, Zunino F.

Int J Cancer. 1993 May 8;54(2):309-14.

PMID:
8098017
44.

Characterization of a topoisomerase II gene rearrangement in a human small-cell lung cancer cell line.

Binaschi M, Giaccone G, Gazdar AF, De Isabella P, Ricotti GC, Capranico G, Zunino F.

J Natl Cancer Inst. 1992 Nov 18;84(22):1710-6. Erratum in: J Natl Cancer Inst 1993 Jan 20;85(2):163.

PMID:
1331483
45.

Relationships among tumor responsiveness, cell sensitivity, doxorubicin cellular pharmacokinetics and drug-induced DNA alterations in two human small-cell lung cancer xenografts.

Pratesi G, Capranico G, Binaschi M, De Isabella P, Pilotti S, Supino R, Zunino F.

Int J Cancer. 1990 Oct 15;46(4):669-74.

PMID:
1976600
46.

Comparison of DNA cleavage induced by etoposide and doxorubicin in two human small-cell lung cancer lines with different sensitivities to topoisomerase II inhibitors.

Binaschi M, Capranico G, De Isabella P, Mariani M, Supino R, Tinelli S, Zunino F.

Int J Cancer. 1990 Feb 15;45(2):347-52.

PMID:
2154411
47.

Evidence of DNA topoisomerase II-dependent mechanisms of multidrug resistance in P388 leukemia cells.

De Isabella P, Capranico G, Binaschi M, Tinelli S, Zunino F.

Mol Pharmacol. 1990 Jan;37(1):11-6.

PMID:
2153905

Supplemental Content

Loading ...
Support Center